Janssen Pharmaceutical Cos.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Janssen Pharmaceutical Cos.
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.
Abbvie, Amgen, Novartis and Novo Nordisk have drugs on the list but haven’t sued yet. While they could add to the ranks of legal opposition, the Court Battle for the IRA is more about philosophy than numbers.
Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.
Despite the advantage of a single pill, the J&J drug could have the potential disadvantage of a narrower label in both the US and EU and Lynparza/Zytiga’s potentially higher efficacy.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.